Matches in Wikidata for { <http://www.wikidata.org/entity/Q63594039> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q63594039 description "assaig clínic" @default.
- Q63594039 description "clinical trial" @default.
- Q63594039 description "clinical trial" @default.
- Q63594039 description "clinical trial" @default.
- Q63594039 description "clinical trial" @default.
- Q63594039 description "ensaio clínico" @default.
- Q63594039 description "ensayo clínico" @default.
- Q63594039 description "ensayu clínicu" @default.
- Q63594039 description "essai clinique" @default.
- Q63594039 description "klinisch onderzoek" @default.
- Q63594039 description "клінічне випробування" @default.
- Q63594039 name "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy" @default.
- Q63594039 type Item @default.
- Q63594039 label "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy" @default.
- Q63594039 prefLabel "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy" @default.
- Q63594039 P1050 Q63594039-8929266E-988B-4E71-9E16-4C35634871B5 @default.
- Q63594039 P1132 Q63594039-66CC158F-2A2D-4119-BF86-ED44DBEEBEC1 @default.
- Q63594039 P1476 Q63594039-2D4AF70E-F4B5-471A-92D7-E2A5DDA753AC @default.
- Q63594039 P17 Q63594039-C96854B4-0DFE-4B10-875D-C4402291B85A @default.
- Q63594039 P1813 Q63594039-73F037FA-9E83-46E3-9FB2-B2AF16DD9F2D @default.
- Q63594039 P2899 Q63594039-56760B22-E63A-42FF-886B-34AEF80E1521 @default.
- Q63594039 P3098 Q63594039-6A6426EE-7D9A-48E7-8BE2-AA1FC2C59D61 @default.
- Q63594039 P31 Q63594039-D96E4A39-6189-41C9-BEDF-E413F21B39C9 @default.
- Q63594039 P4844 Q63594039-1798B626-0E85-4271-8AF6-E2D008318007 @default.
- Q63594039 P4844 Q63594039-18F08A06-8350-46E4-B448-97DE557E2F8E @default.
- Q63594039 P580 Q63594039-F0C322DB-1FEA-483F-81A9-6BB95A1044CB @default.
- Q63594039 P582 Q63594039-87F6E242-C6AD-43A0-8614-941805577E64 @default.
- Q63594039 P6099 Q63594039-BD71AFB7-341E-471E-8EDF-3C4AE8A9DB02 @default.
- Q63594039 P8363 Q63594039-149AE096-54B4-473B-A915-04DF8B3C9B01 @default.
- Q63594039 P921 Q63594039-664DEAD9-1299-4BE7-A724-3960A65E0A0F @default.
- Q63594039 P1050 Q33525 @default.
- Q63594039 P1132 "+640" @default.
- Q63594039 P1476 "A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy" @default.
- Q63594039 P17 Q30 @default.
- Q63594039 P1813 "COSMIC-312" @default.
- Q63594039 P2899 "+18" @default.
- Q63594039 P3098 "NCT03755791" @default.
- Q63594039 P31 Q30612 @default.
- Q63594039 P4844 Q20707748 @default.
- Q63594039 P4844 Q421136 @default.
- Q63594039 P580 "2018-12-10T00:00:00Z" @default.
- Q63594039 P582 "2020-08-01T00:00:00Z" @default.
- Q63594039 P6099 Q42824827 @default.
- Q63594039 P8363 Q78089383 @default.
- Q63594039 P921 Q12078 @default.